Summarized by Masters of Longevity from PR Newswire.
Announcement of an exclusive global collaboration to co-develop and commercialise a claudin-1 targeting monoclonal antibody for rare kidney and liver diseases, including AAV-RPGN, FSGS, and PSC.
Key Takeaways
- CSL will pay Alentis an upfront US$355 million and Alentis can receive up to US$1.2 billion in commercial milestones.
- CSL will fully fund completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial plus Phase 2 studies in FSGS and PSC.
- If commercialised, global profits will be shared 55% to CSL and 45% to Alentis.
